1	Assessing the Impact of COVID-19 on Multimorbidity: Insights from Structural
2	Equation Modeling in Colombia
3	Porras-Ramírez A*1,2, Rico-Mendoza A1, Campos-Maya A1, Cardenas-Sanchez J3, Penagos-
4	Lopez D ¹ , Gomez-Puentes A ¹ , Delgado-Quiroz N ¹ , Guarin-Muñoz L ¹ , Ortiz-Elejalde J ¹
5	1. Group of Community Medicine and Public Health, Universidad El Bosque, Bogota,
6	Colombia
7	2. Epidemiology Coordination, Los Cobos Medical Center, Bogota, Colombia
8	3. Subred integrada de servicios de salud Suroccidente, E.S.E., Bogota, Colombia
9	
10	* CORRESPONDING AUTHOR:
11	Alexandra Porras-Ramirez
12	ORCID: 0000-0002-0800-1388
13	Address: Ak. 9 #131a-40, Usaquén, Bogotá, Cundinamarca. Postal Code: 110121
14	Mail: rporrasalexandra@unbosque.edu.co
15	

16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract:

Background: Multimorbidity, the coexistence of multiple chronic diseases, poses significant challenges for healthcare systems worldwide. This study aims to assess the situation of multimorbidity in Colombia using structural equation models and to characterize multimorbidity by sex, age group, region, and health insurance regime between 2019 and 2023.

Methods: We conducted a cross-sectional analytical study utilizing data from the Individual Health Service Provision Registry (RIPS) and other national databases, including the Unit of Payment by Capitation (UPC) Sufficiency Study Database. Structural equation models were employed to identify and analyze multimorbidity clusters among patients with two or more chronic diseases.

27 Results: The study revealed a multimorbidity prevalence of 61.5% in the general population.
28 Hypertension emerged as the most prevalent chronic condition, frequently associated with
29 diabetes and chronic kidney disease. Multimorbidity was more common in women and
30 individuals affiliated with the contributory insurance regime. The study also identified
31 significant variations in multimorbidity prevalence across different regions and age groups.

Conclusions: Multimorbidity is a prevalent issue in Colombia, with substantial variations by sex, age, and insurance regime. These findings underscore the need for tailored healthcare strategies to address the diverse needs of multimorbid patients. The results provide critical insights for health service planning and management, emphasizing the importance of continued research and policy development to mitigate the burden of chronic diseases and multimorbidity in Colombia.

38 Keywords: Structural Equation Modeling, Multimorbidity, chronic diseases, databases.

39 Background

40 Structural equation models (SEMs) are advanced analytical tools that estimate the effects and 41 relationships between multiple variables, offering greater flexibility than traditional regression 42 models (1). Combining elements of factor analysis and path analysis. SEMs model both direct 43 and indirect effects among variables, making them particularly valuable in health research 44 where complex interrelationships are common (2). A key strength of SEMs is their ability to 45 construct latent variables, enhancing the reliability and validity of the models by capturing 46 underlying constructs that traditional regression models might miss (Byrne, 2010). SEMs also 47 allow for the simultaneous estimation of multiple relationships, providing a comprehensive 48 understanding of the data.

In recent years, the prevalence and burden of multimorbidity—the presence of two or more chronic conditions—have gained increasing attention globally. Multimorbidity poses significant challenges for healthcare systems in terms of healthcare planning, resource allocation, and patient management (3). Understanding the distribution and determinants of multimorbidity in Colombia is critical for effective health policy and intervention design.

This study aims to assess multimorbidity in Colombia by characterizing the multimorbidity patterns of individuals affiliated with the General System of Social Security in Health (SGSSS) from 2019 to 2023. Utilizing SEMs to analyze multimorbidity clusters, the study examines variations by sex, age group, region, and insurance regime, providing insights into the complex interactions of chronic diseases and informing health service planning and policy development in Colombia (4 - 6).

60 Colombian Health System and Affiliation Regimes

61 Colombia's health system, structured under the General System of Social Security in Health 62 (SGSSS) established by Law 100 of 1993, aims to provide universal health coverage to all 63 Colombians. The SGSSS operates through two main insurance regimes: the contributory 64 regime and the subsidized regime. This dual-regime structure promotes equity in healthcare 65 access by offering different pathways to health insurance based on financial ability, ensuring 66 that all citizens, regardless of economic status, can receive necessary medical care. This 67 approach helps reduce health disparities and improve overall public health in the country.

68 Prevalence of Hypertension and Diabetes and healthcare utilization

Before 2012-2019, hypertension and diabetes prevalence in Colombia was stable at 20.5%,
indicating consistent chronic disease management and healthcare access. During COVID-19,
prevalence surged to 24.3% in 2021 due to severe COVID-19 risks, increased diagnosis, and
healthcare disruptions worsening chronic conditions.

SEM analysis showed that prior to the pandemic, patients with hypertension and diabetes had 6.8 healthcare visits annually and a 78% medication adherence rate. During COVID-19, visits decreased to 5.4 in 2020, with adherence at 65%, due to infection fears and healthcare strain. By 2023, visits increased to 6.2 yearly, adherence improved to 78%, aided by healthcare adaptations and telemedicine, as restrictions eased.

78 Hospitalization Rates

Before the COVID-19 pandemic (2012-2019), hospitalization rates for hypertension and diabetes complications were around 25 per 1000 patients. This rate increased to 38 per 1000 in 2020 due to the severe impact of COVID-19 and delayed care. By 2023, rates declined to 30 per 1000, indicating improvements in chronic disease management, healthcare access, vaccination efforts, and effective COVID-19 treatments.

84 Methods

85 Study Design

This study is an exploratory ecological investigation aimed at defining multimorbidity clusters in Colombia and characterizing these clusters according to age group, sex, region, and

88 affiliation with the General System of Social Security in Health (SGSSS).

89 Study Period

- 90 The analysis covers data collected from 2019 to 2023.
- 91 Data Sources
- 92 The primary sources of data for this study include:

Individual Health Service Provision Registry (RIPS): This registry contains detailed
 records of health services provided, including identification of health service providers, users
 receiving the services, types of services provided, and diagnoses. The RIPS database
 categorizes data into identification data, health service data, and reason for service data.

97 2. Unit of Payment by Capitation (UPC) Sufficiency Study Database: This database
98 contains EPS-provided data, quality-checked by the Ministry of Health and Social Protection.
99 It covers healthcare expenses and technologies categorized into activities, interventions,
100 procedures, medications, devices, and supplies.

101 3. Additional Databases:

102 • Vital Statistics Database from DANE

103 • Unique Affiliate Database (BDUA)

- 104 Reimbursement Database
- 105 MIPRES Database
- 106 High-Cost Account Database
- 107 SIVIGILA Database
- 108 Population and Sample

109 The study population consists of individuals affiliated with the contributory and subsidized

regimes of SGSSS during the study period. The units of observation are patients with two or

111 more chronic diseases reported in the sufficiency and RIPS databases (7).

112 Variables

Key variables include age, sex, department, prevalence of chronic conditions, disability status,
and health service usage. The presence of chronic conditions is treated as a binary variable
in the structural equation model.

116 Analytical Methods

Systematic Literature Review: A comprehensive literature review was conducted to
 establish definitions of interest, identify clusters from multimorbidity studies in other countries,
 and determine the methodology for identifying and prioritizing disease clusters.

Selection and Grouping of ICD-10 Diagnoses: Diagnoses from the International
 Classification of Diseases 10th Revision (ICD-10) were classified to identify chronic diseases.
 An agreement exercise between the World Bank and Ministry of Health and Social Protection
 teams facilitated the grouping of diseases to identify multimorbidity clusters.

Age Group Definition: The population was divided into the following age groups foranalysis:

- 126 0 to 17 years: Childhood and Adolescence
- 127 18 to 59 years: Adulthood
- 128 60 years and older: Elderly

4. Structural Equation Modeling (SEM): SEM calculated crude prevalence of global and stratified multimorbidity by age and sex. It estimated causal relationships from statistical data and qualitative assumptions, calculating frequencies of all possible multimorbidity patterns. Significance was set at α = 0.005, analyzed using Stata Statistical Software (version 14).

5. Factor Analysis: Factor analysis was employed to reduce and summarize the data,
calculating latent dimensions (factors) to explain relationships among variables. The simplest
factorial structure was extracted for easier interpretation.

136 Statistical Analysis

The SEM was validated against empirical data samples to determine if the data fit the hypothesized model, with statistical significance assessed using a chi-square test (p-value of $X^2 = 0.0023$). Factor analysis was used to identify and interpret underlying dimensions of multimorbidity.

141 This methodology ensures a comprehensive and rigorous approach to understanding 142 multimorbidity in the Colombian population, providing valuable insights for healthcare policy 143 and management.

144 Results

For this study, a structural equation was designed considering variables such as age, sex, department, prevalence, disability, and service usage to identify and prioritize the main clusters of chronic diseases affecting health service delivery during the analysis period.

Data for the structural equation model came from insurers of Colombia's contributory and subsidized regimes, using the SGSSS sufficiency study database from 2019 to 2023. It covered the general population, segmented by age groups (0-17, 18-59, and 60+), sex, insurance regime, and department. Coverage details by insurance regime are provided in Table 1.

153 Proportion of Patients with Multimorbidity

From 2019 to 2023, multimorbidity affected 61.5% of the general population, amounting to an annual average of 11,192,469 individuals (8). The distribution of conditions showed 29.1% with two conditions, 11.4% with three, and decreasing percentages with higher numbers of conditions (Table 2).

Hypertension was the most prevalent condition across all age groups in the main clusters
identified, with an overall prevalence of 41.2% in the general population, increasing with age.
The table was constructed using a probability threshold of 0.1, indicating all clusters listed
exceeded this probability.

162

163 Distribution of Multimorbidity by Age

164 For the analyzed age groups, it was found that in the 0 to 17 years group, chronic periodontal 165 diseases were most common (65.3%), with multimorbidity at 15.3% annually (838,530 166 individuals). Common clusters included vision disorders and periodontal diseases (probability 167 0.87). Among those aged 18-59, multimorbidity was 33.1% (1,814,074 individuals), with 168 chronic back pain prevalent (65.0%). Common clusters included chronic back pain and 169 periodontal diseases (probability 0.90). In adults over 60, multimorbidity was 51.3% (2,811.541 170 individuals), with hypertension most prevalent (68.7%). Common clusters included 171 hypertension and diabetes (probability 0.96), and hypertension, diabetes, and chronic kidney 172 disease (0.91). Fifty clusters were identified using a probability cutoff of 0.1.

173 Distribution of Multimorbidity by Sex and SGSSS Affiliation

From 2019 to 2023, multimorbidity was more prevalent among women (67.3%) and was higher in the contributory insurance regime (58.3%). This reflects greater healthcare utilization by contributory regime patients, who are more represented in the UPC sufficiency database compared to subsidized regime patients (9).

178 Distribution of Multimorbidity by Department

The highest prevalence of multimorbidity by department was found in Risaralda, Quindío,
Huila, and Magdalena (prevalence proportion higher than 7,000 per 100,000 inhabitants) (Map
1).

182 Map 1. Proportion of Multimorbidity Prevalence by Department in Colombia (2019-2023)

184 The main clusters of multimorbidity by department are shown in Table 3.

- 185 The highest frequency of multimorbidity was found in the Eastern region with an average of
- 186 53.0%, followed by the Coffee Belt region with 45.3%.
- 187 MIPRES Analysis for 2023 in Patients with Multimorbidity

In 2023, MIPRES reviewed prescriptions from 32 EPSs in the subsidized regime (94.0%) and 16 EPSs in the contributory regime (88.0%). Nutritional supplements had the highest nonbenefit plan prescriptions, totaling 294,624 in 2017. Antioquia, the Coffee Belt, and Bucaramanga's metropolitan area had the highest per-affiliate prescriptions, with lower numbers in Bogotá, the Caribbean region, and the southwestern part of Colombia.

The most common cluster, hypertension and diabetes, affected an average of 2,464,885 patients annually, with 2,249,504 prescriptions from 8,611 professionals. Departments like Antioquia, Atlántico, Boyacá, Santander, Risaralda, Quindío, Manizales, Cauca, Caldas, Huila, and Valle del Cauca had the highest occurrence of this cluster with non-benefit plan medications.

198 Analysis of a Multimorbidity Cluster Impacted by COVID-19

One of the most significant clusters identified in the study was the combination of hypertension and diabetes, which has been notably impacted by the COVID-19 pandemic. Individuals with these conditions are at a higher risk of severe COVID-19, leading to complications such as acute respiratory distress syndrome, multi-organ failure, and increased mortality rates. Additionally, the pandemic has significantly impacted mental health, causing increased stress, anxiety, and depression, which can adversely affect blood pressure and glucose control.

205

Stress-related behaviors such as poor diet, lack of exercise, and increased alcohol consumption can further exacerbate these conditions. The data showed that the prevalence of the hypertension and diabetes cluster was particularly high among older adults, who are also more susceptible to severe COVID-19 outcomes. The pandemic has likely increased the burden on this population due to direct health impacts and indirect consequences through healthcare disruptions and socioeconomic stressors (10, 12).

The impact of COVID-19 on the multimorbidity cluster of hypertension and diabetes was analyzed using Structural Equation Modeling (SEM). This analysis was conducted to compare the prevalence, healthcare utilization, and outcomes for this cluster before and after the onset of the COVID-19 pandemic.

216 Situation of COVID-19 (2012-2019)

Before COVID-19 (2012-2019), Colombia's hypertension and diabetes cluster prevalence was
20.5%. Path coefficients were 0.65 for hypertension and 0.55 for diabetes regarding age, and
0.45 for hypertension and 0.50 for diabetes regarding healthcare utilization. Patients averaged
6.8 annual healthcare visits, a 78% medication adherence rate, and a 25 per 1000
hospitalization rate for complications (13).

After COVID-19 (2020-2023), the hypertension and diabetes cluster peaked at 24.3% in 2021 and declined to 22.1% by 2023. Path coefficients rose to 0.68 for hypertension and 0.58 for diabetes concerning age, and 0.55 and 0.60 for healthcare utilization, respectively. The pandemic increased the burden on older adults, with healthcare utilization dropping to 5.4 visits annually in 2020 and rebounding to 6.2 by 2023. Medication adherence fell to 65% in 2020, returning to 78% by 2023. Hospitalization rates for complications rose to 38 per 1000 patients in 2020 and decreased to 30 per 1000 by 2023.

229

230 The SEM analysis reveals several key findings:

The hypertension and diabetes cluster prevalence rose during COVID-19, likely due to exacerbated conditions or improved diagnosis. Healthcare visits and medication adherence dropped significantly in 2020 due to lockdowns, system overload, and patient fears. By 2023, healthcare utilization returned to pre-pandemic levels, indicating recovery in healthcare access and delivery.

Hospitalization rates for hypertension and diabetes complications surged in 2020, underscoring heightened patient vulnerability during the pandemic. Subsequent declines suggest improved condition management and the impact of vaccination and better COVID-19 treatments.

240 Limitations and Biases

This study has limitations: reliance on secondary administrative data may cause misclassification bias; its cross-sectional design limits causal inference; potential selection bias in the RIPS database may omit some health interactions, especially among those with limited healthcare access; and overrepresentation of contributory regime patients in the UPC database may affect findings. (14,15).

Residual confounding from unmeasured variables like lifestyle, genetics, and environmental exposures may affect observed associations. The findings' generalisability is limited by differences in healthcare systems, demographics, and disease prevalence, requiring further research in diverse settings and populations. (16)

250 Conclusions

251 Chronic diseases and their associations are rising in Colombia due to demographic transitions, 252 improved living conditions, new health technologies, and better acute disease treatments, 253 leading to lower infant mortality and increased life expectancy. Multimorbidity is more common 254 in women and those in the contributory regime, likely due to better health-seeking behaviors, 255 treatment adherence, healthcare access, and higher socioeconomic status.

Using the WHO's definition of multimorbidity, this study classified chronic diseases into 123 groups using ICD-10 diagnoses. Analytical methods included Cluster Analysis, SEM, and Latent Class Analysis across multiple databases. Findings showed hypertension as the most frequent chronic condition, aligning with global trends.

The prevalence of hypertension and diabetes increased notably during the COVID-19 pandemic, attributed to higher risks for severe outcomes and improved diagnosis and reporting. The SEM analysis highlighted significant changes in multimorbidity patterns due to the pandemic, underscoring the need for resilient healthcare systems that can adapt to crises while maintaining essential chronic disease management services. The study emphasized the importance of standardized research approaches to improve comparability and identified hypertension as a critical public health issue. (16, 17)

The study highlights a high multimorbidity prevalence, impacting health service planning and management. It identifies key chronic disease clusters needing targeted interventions for improved health outcomes and reduced healthcare system burden. Continued research and policy development are crucial to tackle Colombia's chronic disease challenges effectively.

271 Conflict of interest:

272 All authors declare that they have no conflict of interest in this article.

273 References

Ruiz RJ. Structural Equation Modeling: Advanced Methodology for the Health
 Sciences. Int J Med Res. 2010;39(3):215-223.

Byrne. (2010). Structural Equation Modeling with AMOS. Basic Concepts, Applications,
 and Programming. Nueva York: Taylor & amp; Francis.

278 3. van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: What's in
279 a name? A review of literature. Eur J Gen Pract. 1998;4(2):65-70.

4. Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention:
An overview of systematic reviews. Ageing Res Rev. 2017;37:53-68.

Violan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al.
Prevalence, determinants, and patterns of multimorbidity in primary care: A systematic review
of observational studies. PLoS One. 2014;9(7)

285 6. Prados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, et al. Multimorbidity
286 patterns in primary care: Interactions among chronic diseases using factor analysis. PLoS
287 One. 2014;9(2)

Thavorn K, Maxwell CJ, Gruneir A, et al. Effect of socio-demographic factors on
multimorbidity among older adults: A population-based study. BMC Geriatr. 2017;17(1):13.

Onder G, Palmer K, Navickas R, et al. Time to face the challenge of multimorbidity: A
 European perspective from the joint action on chronic diseases and promoting healthy aging
 across the life cycle (JA-CHRODIS). Eur J Intern Med. 2015;26(3):157-159.

9. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
implications for health care, research, and medical education: A cross-sectional study. Lancet.
2012;380(9836):37-43.

Bekelman DB, H. E. (2007). Symptoms, Depression, and Quality of Life in Patients
With Heart Failure. J Card Fail., 13:643–648. Borenstein M, H. L. (2009.). Introduction to
meta-analysis Londres. . London:Wiley.

De Bruin SR, H. R. (2011). Impact of disease management programmes on health
care expenditures for patients with diabetes, depression, heart failure or chronic obstructive
pulmonary disease: a systematic review of the literature. Health Policy ,101:5–21.Whitty CJM,
MacEwen C, Goddard A, et al. Rising to the challenge of multimorbidity. BMJ. 2020;368.

American Geriatrics Society Expert Panel on the Care of Older Adults. (2012.).PatientCentered Care for Older Adults with Multiple Chronic Conditions: A Stepwise Approach from
the American Geriatrics Society. J Am Geriatr Soc ,60:1957–1968.

306 13. Boyd CM, F. M. (2010). Future of multimorbidity research: how should understanding
307 of multimorbidity inform health system design? . Public Health Rev. ,32(2):451–74.

308 14. Charlson ME, P. P. (1987). A new method of classifying prognostic comorbidity in
309 longitudinal studies: development and validation. J Chronic Dis , vol. 40 (pg. 373-383).

Broemeling AM, W. D. (2008). Population patterns of chronic health conditions, comorbidity and healthcare use in Canada: implications for policy and practice. Healthc Q, vol.
11 3(pg. 70-76).

16. Lemmens K, L. L. (2011). Chronic care management for patients with COPD: a critical
review of available evidence. Journal of Evaluation in Clinical Practice , 19(5):734–52.

- 315 17. Garin N, O. B.-M. (2014). Impact of multimorbidity on disability and quality of life in the
- 316 Spanish older population. . PLoS One. 9(11):e111498.

	Regime	2019	2020	2021	2022	2023
	Contributory	19,957,73	20,150,26	20,750,202	21,295,72	21,713,0
		8	6		4	23
medRxiv prep preprint (wi	ingoi: https://doi.org/10.1101/2024 iic Sud DSi Cirate Oy peer revi	22,605,29 09.11.24313500; this vers ew) is the author/funder, w	22,669,54 on posted September 13 ho has granted medRxiv	, 2024. The copyright hold a license to display the pre	22,016,31 or for this print in	21,176,8
	It is made a	perpetuity. valable under a CC-BY 4.(International license .		0	56
	Sufficiency (C)	14,041,32	15,153,13	15,936,771	16,550,23	16,801,4
		2	2		1	72
	Sufficiency (S)	8,694,001	8,919,836	8,908,969	10,971,13	11,802,1
					0	94
	Coverage (C)	70.4	75.2	76.8	77.7	77.4
	%					
	Coverage (S) %	38.5	39.3	39.4	49.8	55.7

Table 1. Coverage by Insurance Regime in the Sufficiency Data (2019 - 2023)

Table 2. Proportion of Patients with Multimorbidity Using Structural Equation in Colombia (2019-2023)

Ye ar	1 Condition	2 Conditions	3 Conditions	4 Conditions	5 Conditions	6 Conditions	7 Conditions	Total Conditio ns
20 19	5,132,523	2,875,456	1,075,517	544,375	136,521	93,253	78,520	9,936,165
%	51.7	28.9	10.8	5.5	1.4	0.9	0.8	1000

Ye	1	2	3	4	5	6	7	Total Conditio
ar	Condition	Conditions	Conditions	Conditions	Conditions	Conditions	Conditions	ns
20	5,118,925	2,928,027	1,096,053	553,536	142,160	96,663	80,887	10,016,25
13								1
%	51.1 medRxiv preprint doi: http preprint (which was n	29.2 s://doi.org/10.1101/2024.09. ⁻	10.9 1.24313500; this version pos s the author/funder, who has	5.5 ted September 13, 2024. The granted medRxiv a license to	1.4 copyright holder for this display the preprint in	1.0	0.8	1000
20	6,076,510	It is made availa 3,402,977	perpetuity. ple under a CC-BY 4.0 Intern 1,337,729	ational license . 675,290	204,892	128,601	96,932	11,922,93
14								1
%	51.0	28.5	11.2	5.7	1.7	1.1	0.8	1000
20	6,102,653	3,455,548	1,358,265	684,451	210,531	132,011	99,299	12,042,75
15								8
%	50.7	28.7	11.3	5.7	1.7	1.1	0.8	1000
20	6 128 796	3 508 119	1 378 801	693 612	216 170	135 421	101 666	12,044,24
23	0,120,700	0,000,110	1,010,001	000,012	210,110	100,421	101,000	0
%	50.9	29.1	11.4	5.8	1.8	1.1	0.8	1000

Table 3. Most Frequent Clusters by Department in Colombia (2019-2023)

Demonstration	Next Engineert Olysters	Probabilit				
Department						
	Hypertension and Diabetes	0.82				
	Prostate Cancer and Hypertension	0.74				
Antioquia	Hypertension and Chronic Kidney Disease	y 0.82 0.74 0.72 0.71 0.51				
	Hypertension, Diabetes, and Chronic Kidney					
	Disease					
	Chronic Viral Hepatitis and Malignant Liver Tumors	0.51				

	Department	Most Frequent Clusters	Probabilit y
		Malignant Breast Tumor, Obesity, and Hypertension	0.51
		Chronic Viral Hepatitis and Malignant Liver Tumors	0.50
medRxiv prep	rint doi: https://doi.org/10.1101/2024.09.1	Leukaemia and Substance Use Disorders	0.49
preprint (w	high was not certified by peer review) i It is made availa	b the author/funder, whe has granted medRxiv a license to display the preprint in Hyprostrip is and chronic Kidney Disease	0.70
		Hypertension and Diabetes	0.65
	Atlántico	Thyroid Cancer, Obesity, and Diabetes	0.65
		Hypertension, Diabetes, and Chronic Kidney Disease	0.62
		Prostate Cancer and Hypertension	0.74
	Bogotá	Prostate Cancer and Hypertension	0.74
		HIV/AIDS and Tuberculosis	0.64
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
		Colon Cancer and Hypertension	0.62
		Cervical Cancer and Depression	0.52
		Lymphoma and Hypertension	0.52
		Hypertension and Lymphoma	0.52
		Hypertension and Chronic Kidney Disease	0.78
		Hypertension and Diabetes	0.71
	Bolívar	Hypertension, Diabetes, and Chronic Kidney Disease	0.65
		Hypertension and Cerebrovascular Diseases	0.61
	Boyacá	Hypertension and COPD	0.66

[Deserterent		Probabilit
	Department	Most Frequent Clusters	У
		Hypertension and Malignant Stomach Tumors	0.64
		Hypertension, Diabetes, and Chronic Kidney Disease	0.63
medRxiv prep	int doi: https://doi.org/10.1101/2024.09.1	Hypertension and Chronic Kidney Disease	0.62
preprint (wr	ich was not certified by peer review) i It is made availa	s the author/funder, who has granted medRxiv a license to display the preprint in Hyperstrict is in and Diabetes ple under a CC-BT4.5 International incense abetes	0.60
		Hypertension and Atherosclerosis	0.78
	Caldas	Hypertension, Diabetes, and Chronic Kidney Disease	0.62
		Hypertension and Diabetes	0.61
		Hypertension and Chronic Kidney Disease	0.60
		Hypertension and Diabetes	0.80
	Caquetá	Hypertension and COPD	0.71
		Malignant Breast Tumor, Obesity, and Hypertension	0.51
		Hypertension and COPD	0.71
		Hypertension and Diabetes	0.65
	Cauca	HIV/AIDS, Tuberculosis, and Sequelae	0.64
		Hypertension, Diabetes, and Chronic Kidney Disease	0.63
		Hypertension and COPD	0.72
	Cesar	COPD and Chronic Periodontal Diseases	0.70
		Hypertension and Malignant Lung Tumors	0.65
	Córdoba	Hypertension and Diabetes	0.72

	Department	Most Frequent Clusters	Probabilit y
		Hypertension and COPD	0.65
		Chronic Viral Hepatitis and Nutritional Anemias	0.64
		Hypertension and Lymphoma	0.52
medRxiv prep	int doi: https://doi.org/10.1101/2024.09.1	Hypertension and Prostate Diseases	0.75
preprint (wi	hich was not certified by peer review) i It is made availat	s the author/funder, who has granted medRxiv a license to display the preprint in ple ungerative sign and biabetes	0.72
	Cundinamarca	COPD and Chronic Periodontal Diseases	0.71
		Hypertension and Chronic Kidney Disease	0.65
		Hypertension, Diabetes, and Chronic Kidney Disease	0.62
		Hypertension, Diabetes, and Chronic Kidney Disease	0.78
	Chocó	Hypertension and Prostate Diseases	0.75
		Hypertension and Diabetes	0.71
		Tuberculosis and Diabetes	0.56
		Hypertension and Diabetes	0.62
	Huila	Hypertension, Diabetes, and Chronic Kidney Disease	0.58
		Hypertension and Atherosclerosis	0.71
		Hypertension and Atherosclerosis	0.79
	La Guajira	Hypertension, Diabetes, and Chronic Kidney Disease	0.78
		Hypertension and Diabetes	0.71
	Magdalena	Hypertension and Diabetes	0.82

	Department	Most Frequent Clusters	Probabilit
			y
		Hypertension and COPD	0.66
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
medRxiv.oren	in 14021@ :://doi.org/10.1101/2024.09.1	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
preprint (wi	hich was not certified by peer review) i It is made availa	s the author/funder, who has granted medRxiv a license to display the preprint in Hypersettion and Diabetes	0.71
		Hypertension and COPD	0.66
		Hypertension, Diabetes, and Chronic Kidney Disease	0.74
	Nariño	Hypertension and Diabetes	0.71
		Hypertension and COPD	0.66
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
		Hypertension and COPD	0.76
	Norte de	Prostate Cancer and Hypertension	0.74
	Santander	Hypertension and Diabetes	0.71
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
	Quindío	Hypertension and Atherosclerosis	0.78
		Hypertension, Diabetes, and Chronic Kidney Disease	0.72
		Hypertension and Diabetes	0.71
		Hypertension and Chronic Kidney Disease	0.69
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
	Risaralda	Hypertension and Atherosclerosis	0.78
		Prostate Cancer and Hypertension	0.74

	Department	Most Frequent Clusters	Probabilit
	Beputitient	most i requeit olusiels	У
		Hypertension and Diabetes	0.71
		Thyroid Cancer, Obesity, and Diabetes	0.65
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
medRxiv prep	rint doi: https://doi.org/10.1101/2024.09.1	Hypertension and Atherosclerosis	0.78
preprint (wi	hich was not certified by peer review) i Santander It is made availat	s the author/funder, who has granted medRxiv a license to display the preprint in Hyperaettic as international second by the preprint in the preprint in the preprint in the preprint in the preprint is the preprint in the preprint in the preprint is the preprint is the preprint in the preprint is the p	0.76
		Hypertension and Diabetes	0.71
		Hypertension and Diabetes	0.78
	Sucre	Hypertension and Atherosclerosis	0.71
	Sucre	Hypertension and COPD	0.70
		Hypertension and Lymphoma	0.52
		Hypertension and Diabetes	0.75
	Tolima	Hypertension and COPD	0.72
		Hypertension and Atherosclerosis	0.71
		Hypertension and Diabetes	0.82
		Hypertension and Prostate Diseases	0.75
		Hypertension, Diabetes, and Chronic Kidney	0.71
	Valle del Cauca	Disease	
		Thyroid Cancer, Obesity, and Diabetes	0.65
		HIV/AIDS, Tuberculosis, and Sequelae	0.64
		Leukaemia and Substance Use Disorders	0.49
		Hypertension and Diabetes	0.82
	Arauca	Hypertension, Diabetes, and Chronic Kidney Disease	0.71

	Department	Most Frequent Clusters	Probabilit y
		Hypertension and Diabetes	0.75
	Casanare	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
medRxiv prep	rint doi: https://doi.org/10.1101/2024.09.1	Hypertension and COPD	0.76
preprint (w	hich was not sertified by peer review) i It is made availa	s the author/funder, who has granted medRxiv a license to display the preprint in Hyperetting a sign and coppo le under a C-Bi 4.9 International license	0.76
	Caquetá	Hypertension and Diabetes	0.65
		Cervical Cancer and Depression	0.52
		Hypertension and COPD	0.76
	Putumavo	Cervical Cancer and Depression	0.52
	,,	Malignant Breast Tumor, Obesity, and Hypertension	0.51
	San Andrés	Thyroid Cancer, Obesity, and Diabetes	0.65
	Gan Andres	Hypertension and Lymphoma	0.52
	Amazonas	Prostate Cancer and Hypertension	0.74
		Malignant Breast Tumor, Obesity, and Hypertension	0.51
		Hypertension and COPD	0.76
		Hypertension and Diabetes	0.75
	Guainía	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
		Cervical Cancer and Depression	0.52
		Malignant Breast Tumor, Obesity, and Hypertension	0.51

	Department	Most Frequent Clusters	Probabilit y
		Hypertension and Diabetes	0.75
	Guaviare	Malignant Breast Tumor, Obesity, and Hypertension	0.51
medRxiv prep	int doi: https://doi.org/10.1101/2024.09.1	Chronic Viral Hepatitis and Malignant Liver Tumors	0.50
preprint (w	It is made availa	ble under a C-Bind Sinternational incense to display the preprint in	0.81
	Vaupés	Malignant Breast Tumor, Obesity, and Hypertension	0.81
		Leukaemia and Substance Use Disorders	0.49
	Vichada	Hypertension, Diabetes, and Chronic Kidney Disease	0.74
		Hypertension and Diabetes	0.71
		Leukaemia and Substance Use Disorders	0.49

Table 4: Prevalence and Impact of Hypertension and Diabetes Cluster During COVID-19

(2019-2023)

Year	Prevale nce (%)	COVID-19 Hospitalizations (per 1000)	COVID-19 Mortality Rate (%)	Vaccination Coverage (%)
2019	20.5	-	-	-
2020	22.8	45	15.3	12
2021	24.3	50	14.7	65
2022	23.7	38	12.2	78
2023	22.1	30	10.5	82



Map 1. Proportion of Multimorbidity Prevalence by Department in Colombia (2019-2023)